Deep Track Capital Reports New 9.53% Stake in Ocular Therapeutix, Inc. (OCUL)

On May 15, 2026, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A reporting a significant increase in their position in Ocular Therapeutix, Inc. (OCUL). The filing indicates that the reporting persons now beneficially own 20,850,000 shares of common stock, representing a 9.53% ownership stake in the company. This is a substantial increase from the previously reported 0.0% ownership. The total share count includes 1,163,718 shares issuable upon the exercise of pre-funded warrants, which are subject to a 9.99% maximum ownership limitation. David Kroin, as the Managing Member of the General Partner of the Investment Adviser, may be deemed to have shared voting and dispositive power over these securities. The filing was made under Rule 13d-1(c), certifying that the shares were acquired for investment purposes and not to influence or change the control of the issuer. This move establishes Deep Track Capital as a major institutional shareholder in the Bedford-based biopharmaceutical firm.